FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Nootropic In Vitro Research Only

Selank: Anxiety Research, Stress Resilience & Cognitive Enhancement

800+ Hippocampal Stress Genes Modulated

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the immune-modulating tetrapeptide Tuftsin with three amino acids added for stability. Approved as an anxiolytic in Russia since 2009, it demonstrated equivalent efficacy to medazepam (a benzodiazepine) in a randomised controlled trial with zero sedation, cognitive impairment, or withdrawal effects. It modulates over 800 genes in the rat hippocampus under stress conditions.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧠

GABA-A Allosteric Modulation

Positively modulates GABA-A receptors through an allosteric mechanism similar to benzodiazepines, producing anxiolytic effects without downregulation or physical dependence.

🧬

BDNF Upregulation

Significantly increases Brain-Derived Neurotrophic Factor mRNA and protein in rat hippocampus and frontal cortex — effects persisting beyond the treatment period.

⚗️

Enkephalin Metabolism Modulation

Inhibits enkephalin breakdown (endogenous opioid peptides), enhancing mood and stress tolerance without activating classical opioid receptors.

🛡️

Immune Modulation (Tuftsin Origin)

Upregulates IL-2 production and natural killer cell activity — inherited from its Tuftsin backbone — providing simultaneous anxiolytic and immune-supporting properties.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

📊
=
Efficacy vs. Medazepam
RCT — 62 GAD patients (Semenova 2010)
🧬
800+
Genes Modulated
Rat hippocampus under stress
💊
2009
Approved (Russia)
Trade name: Selanc
🛡️
0
Dependence Risk
No withdrawal in clinical trials

Selank vs. Medazepam — Anxiety Reduction & Side Effect Profile

Anxiolytic Efficacy
85
Cognitive Impact
2
Sedation
3
Dependence Risk
1
BDNF Elevation
72

Selank scores. Source: Semenova et al. (2010) Bull Exp Biol Med. PMID 21161138.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

96%

Tolerability

Low Severity
0%

Dependence Risk

Low Severity
5%

Mild Fatigue (Rare)

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.

RESEARCH CITATIONS

Primary literature — links open PubMed or original journal source

Syntra Compound Library

View SELANK specifications, batch data, and Certificate of Analysis in the Syntra research compound catalogue.

View SELANK in the Syntra Compound Library →

For in vitro laboratory research use only. Not for human consumption.

← Back to Peptide Research Library
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →